Cargando...
Toxicity management for patients receiving novel T-cell engaging therapies
PURPOSE OF REVIEW: Recent clinical trials using T-cell engaging immunotherapies such as bispecific antibodies which target T cells and tumor cells, as well as engineered T cells that express targeting and activation molecules known as chimeric antigen receptors, have demonstrated powerful proof of c...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2014
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4198063/ https://ncbi.nlm.nih.gov/pubmed/24362408 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MOP.0000000000000043 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|